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Background:  Left  ventricular  (LV)  diastolic  dysfunction  in  patients  with chronic  kidney  disease  (CKD)  is  of
a complex  nature  and  is the  predominant  cause  of  congestive  heart  failure  in this  group  of patients.  This
work  aimed  to  evaluate  the  potential  effect  of disturbances  in  calcium-phosphorus  (Ca-P)  metabolism  in
patients  with  CKD  on  LV  diastolic  function  as assessed  by  echocardiography.
Materials  and methods:  The  study  group  consisted  of  81  ambulatory  patients  with  CKD,  stages  2–5,  with
preserved  LV  systolic  function–LV  ejection  fraction  >50%  and  with  sinus  rhythm.  Standard  echocardiogra-
phy  was  performed  in all patients  with  tissue  Doppler  echocardiography  for  the  evaluation  of  the  systolic
velocity and  both  diastolic  velocities  of LV  (EmLV  and  AmLV).  The  following  laboratory  parameters  were
measured:  serum  creatinine  concentration,  estimated  glomerular  ﬁltration  rate,  and  the levels  of  urea,
P, Ca, parathormone,  platelet  count,  hemoglobin  level,  and  N-terminal  pro-B-type  natriuretic  peptide
(NT-proBNP)  levels.  Patients  were  divided  into  two  groups  according  to the  results  of EmLV:  group  with
LV  diastolic  dysfunction  (EmLV  < 8 cm/s)  DF (+)  and  group  with  normal  LV diastolic  function  DF  (−),  when
EmLV  was  ≥8 cm/s.
Results:  Patients  in DF (+)  group,  as  compared  to DF (−)  patients,  manifested  a  lower  serum  Ca
level  and an  elevated  NT-proBNP  level  [9.03  ±  0.76  mg/dL  vs  9.44 ±  0.78  mg/dL,  p  = 0.02,  and  257.9
(32.6–12,633)  pg/ml  vs  149  (11.7–966)  pg/ml,  p =  0.035,  respectively].  The  area  under  the receiver  oper-
ating  characteristics  (ROC)  curve  of  Ca for diastolic  dysfunction  was  0.627,  95%  CI  (0.511–0.734),  p  = 0.04,
whereas  ROC  derived  Ca  value  of  ≤9.82  mg/dL  was characterized  by  a sensitivity  of 91.8% and  speciﬁcity
of  38.1%  for  diagnosing  LV  diastolic  dysfunction.  The  only  independent  variable  predicting  LV  diastolic
dysfunction  as measured  by  a multivariate  logistic  regression  analysis  was  Ca  level  ≤  9.82  mg/dL  with
odds  ratio  =  8.81  (95%  CI 1.49–51.82),  p = 0.014.
Conclusions:  Hypocalcemia  is  an  independent  predictive  factor  for LV  diastolic  dysfunction  in patients
3  Jap
with  CKD.
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Left ventricular (LV) diastolic dysfunction in patients with
hronic kidney disease (CKD) is of a complex nature and is the pre-
ominant cause of congestive heart failure in this group of patients.
he most frequent cause, substantially described in literature, is
V hypertrophy, and is mainly associated with arterial hyperten-
ion and anemia. Additionally, the development of LV diastolic
ysfunction can result from disturbances in calcium-phosphorus
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(Ca-P) metabolism. In patients with CKD, signiﬁcant relationships
have been already reported between altered Ca-P metabolism and
blood cell morphology and myocardial function and arterial bed
function, including coronary vessels. In CKD patients, depending
on the stage of the disease, the biochemical disturbances are dom-
inated by a decreased level of serum Ca, especially its ionized
fraction (Ca2+) in plasma, lower level of the biologically active form
of vitamin D, i.e. calcitriol, elevated serum P, and parathormone
(PTH) levels. Clinical consequences of these abnormalities include
renal osteodystrophy and extraskeletal calciﬁcations, mainly in
the cardiovascular system. The latter signiﬁcantly affect the pro-
gressively developing dysfunction of the cardiovascular system in
CKD patients, most likely associated with damage to the small
vessels, including coronary vessels, as a result of Ca-P deposits
and accelerated atherosclerosis [1,2]. It has been proven that
vier Ltd. All rights reserved.
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yperphosphatemia (above 5.0 mg/dL), high values of the Ca-P
roduct (Ca x P – above 55 mg2/dL2), as well as high levels of PTH
re correlated with higher prevalence of CKD and mortality rates in
his population of patients [2,3]. Hyperphosphatemia is currently
onsidered as the key biochemical disturbance in uremia, leading to
rogressive vascular calciﬁcations. The term “calciﬁcation” is used
n the literature, whereas in fact the essence of this process involves
he synthesis of calcium phosphates (hydroxyapatites), and conse-
uently the value of Ca x P index is particularly important here.
The direct effect of hypocalcemia on the cardiovascular sys-
em in the complicated metabolic circumstances occurring in CKD
emains unresearched. Neither data in the literature, nor wide-
anging research has been found proving a direct correlation
etween a lower serum Ca level in CKD patients and cardiac func-
ion.
Reports, published recently, concerning the relation between
iet Ca intake, its supplementation, and cardiovascular risk and
ortality are not unanimous. Some studies indicate that Ca supple-
entation is associated with a higher cardiovascular risk, whereas
thers contradict this thesis [4–6]. In our study, we hypothesized
hat disturbances in Ca-P metabolism, and hypocalcemia in partic-
lar, can contribute to LV diastolic dysfunction.
aterials and methods
The study group consisted of 81 ambulatory patients with
KD, stages 2–5, with preserved LV systolic function deﬁned
y LV ejection fraction (LVEF) > 50% and lack of regional wall
otion abnormalities, and with sinus rhythm. Exclusion criteria
omprised: non-sinus rhythm, LV systolic dysfunction, previ-
us myocardial infarction, cardiomyopathy, severe valvular heart
isease, and pericardial ﬂuid above 10 mm  at diastole. Diagnos-
ic criteria for CKD were consistent with the National Kidney
oundation Kidney Disease Outcomes Quality Initiative (KDOQI)
tandards [7]. Body mass index (BMI) was also calculated for each
atient.
chocardiography
Standard echocardiography was performed for all patients
sing a GE 6S (GE, Fairﬁeld, CT, USA) device with 2.5–3.5 MHz
ransducer. In order to increase the credibility of the obtained
chocardiographic results, the physician who performed the exam-
nation did not know the biochemical parameters of the patients.
he examinations were conducted when the patients had been
tabilized. Particular attention was placed on retaining optimal
ydration.
Using the M-MODE in the parasternal long-axis view the
ollowing parameters were assessed: LV end-diastolic dimen-
ion (LVEDD), right ventricular end-diastolic dimension (RVEDD),
eft atrial diastolic dimension (LAD), interventricular septal dia-
tolic diameter (IVSd), and LV posterior wall dimension at
iastole (LVPWd). Additionally, LV fractional shortening (LVFS) was
ssessed. In the four chamber view, LV ejection fraction (LVEF) was
alculated with the modiﬁed Simpson’s rule [8]. LV mass (LVM) was
alculated with the formula recommended by the American Soci-
ty of Echocardiography modiﬁed by Devereux [9]. The obtained
esults of LVM were indexed by the body surface area of the patient
nd presented as LVM index (LVMI).
In order to assess transmitral ﬂow, pulsed wave Doppler
chocardiography was performed in a four chamber view. The
oppler gate was placed at the level of the mitral annulus and a
wo-phase ﬂow proﬁle was obtained, including: early (E) and late
A) transmitral velocities, deceleration time (DT) of the E wave; E/A
atio was also calculated [8].rdiology 63 (2014) 198–204 199
Tissue Doppler echocardiography
In pulsed wave tissue Doppler echocardiography, diastolic and
systolic velocities were measured by placing the Doppler gate on
the lateral mitral annulus at the posterior leaﬂet of the mitral valve.
The following parameters were measured: peak mitral annular
systolic velocity (SmLV), peak early diastolic velocity (EmLV), and
peak late diastolic velocity (AmLV) of the lateral part of the exam-
ined annulus [10]. All parameters were calculated as the mean of
measurements taken in 3 consecutive cardiac cycles. LV diastolic
dysfunction was  deﬁned as EmLV < 8 cm/s [11].
Biochemical tests
On the day of the echocardiographic examination, the following
laboratory parameters were recorded for all patients: serum cre-
atinine concentration, estimated glomerular ﬁltration rate (eGFR)
evaluated by the modiﬁed MDRD formula, as well as the serum
levels of urea, P, Ca, PTH, platelets (PLT), and hemoglobin (Hb). Addi-
tionally, N-terminal proB-type natriuretic peptide (NT-proBNP)
levels were calculated by immunoassay with the Stratus® CS Acute
CareTM (Siemens, Munich, Germany).
Patients were divided into two groups depending on the
results of EmLV: DF (+) group with LV diastolic dysfunction
(EmLV < 8 cm/s) and DF (−) group with normal LV diastolic function,
when EmLV ≥ 8 cm/s [11].
Statistical analysis
Values of parameters with a normal distribution are presented
as a mean ± standard deviation, whereas values with non-normal
distributions are expressed as median and range. In order to com-
pare both groups, Student’s t-test and the Mann–Whitney test were
used, depending on the parameter distribution. 2 test was used to
compare qualitative variables in contingency tables.
The correlation between the statistically signiﬁcant parameters
for both groups and the parameter indicating LV diastolic dysfunc-
tion (EmLV < 8 cm/s) is also presented.
Receiver operating characteristic (ROC) analysis curves served
to determine the optimal cutoff points for identifying patients with
LV diastolic dysfunction.
In order to determine the diagnostic value of the evaluated
parameters, univariate and multivariate logistic regression was
employed. To assess the diagnostic value, odds ratio for particu-
lar laboratory and echocardiographic parameters was calculated.
In the analysis the parameters were treated either continuously or
dichotomously using their values as determined in the ROC analy-
sis.
All patients consented in writing for inclusion in the research.
The study protocol was  approved by the Bioethics Committee (no.
555/2011).
Results
The study group consisted of 81 ambulatory patients with
CKD. CKD etiology in the study group included: hypertensive
and ischemic nephropathy in 40 patients, glomerulonephritis in
5 patients, interstitial nephritis in 8 patients, diabetic nephropathy
in 3 patients, polycystic kidney disease in 6 patients, autoimmune
disease in 1 patient, whereas unknown etiology was present in
18 cases. Fifteen patients had stage 2 CKD (eGFR 89–60 ml/min),
41 patients had stage 3 CKD (eGFR 59–30 ml/min), 18 patients –
stage 4 CKD (eGFR 29–15 ml/min), and 7 patients – stage 5 CKD
(eGFR < 15 ml/min).
The DF (+) group – with LV diastolic dysfunction (EmLV < 8 cm/s)
consisted of 39 patients; 42 patients were included in the group
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ithout LV diastolic dysfunction – DF (−) group (EmLV ≥ 8 cm/s).
able 1 presents the clinical characteristics of both study groups.
Patients in both groups did not differ in age, sex, body mass
ndex (BMI), presence of arterial hypertension, type 2 diabetes, and
KD stage.
Pharmacological treatment of patients from both groups is pre-
ented in Table 2.
There were no statistically signiﬁcant differences between both
roups regarding the frequency of hypotensive drugs administra-
ion.
Results of laboratory tests for both groups are presented in
able 3.
Patients with LV diastolic dysfunction, as compared to patients
ith normal diastolic function, were characterized by signiﬁ-
antly lower serum Ca levels and higher NT-proBNP levels. No
ifferences were observed for the following parameters: the
GFR level and concentrations of creatinine, urea, P, PLT, Hb,
nd PTH.
Parameters obtained in standard echocardiography in both
roups of patients are presented in Table 4.
In standard echocardiography, patients with LV diastolic dys-
unction, as compared to patients with normal LV diastolic function,
ere characterized by higher values of LVMI, higher values of IVSd
nd LV posterior wall dimension (LVPWd), smaller early mitral ﬂow
elocities (E), and smaller mitral ﬂow E/A ratios. No differences
ere noted for the following parameters: LVEDD, RVEDD, LVEF,
AD, FS, A and DT.
able 1
eneral characteristics of both groups.
Parameter Total (n = 81) DF (+) grou
Age (years) 67.8 ± 12 69.8 ± 12.3
Sex  (M/F) 32/49 19/20 
Diabetes, n (%) 22 (27) 12 (30) 
Hypertension, n (%) 70 (86) 34 (87) 
Stage  2 CKD 15 (18) 5 (13)
Stage  3 CKD 41 (50) 17 (43) 
Stage  4 CKD 18 (22) 12 (30) 
Stage  5 CKD 7 (8) 5 (13) 
BMI  (kg/m2) 29.1 ± 5.4 28.4 ± 5.3 
F (+), group with diastolic dysfunction; DF (−), group without diastolic dysfunction; CKD
able  2
reatment in both groups.
Parameter Total (n = 81) DF (+) group 
Beta blockers 38 (47) 21 (54) 
ACE  inhibitors 39 (48) 21 (54) 
AT1 blockers 11 (14) 6 (15) 
Diuretics 51 (63) 28 (72) 
Ca  blockers 32 (39) 17 (44) 
Statins 30 (37) 18 (46) 
F (+), group with diastolic dysfunction; DF (−), group without diastolic dysfunction; ACE
able  3
iochemical characteristics of patients from both groups.
Parameter Total (n = 81) DF (+
Creatinine (mg/dL) 1.47 (0.68–6.31) 1.53 
eGFR  (ml/min/1.73 m2) 37 (6–89) 37 (6
Urea  (mg/dL) 57 (19–204) 59 (2
P  (mg/dL) 3.7 (2.2–6.8) 3.8 (2
Ca  (mg/dL) 9.25 ± 0.79 9.03 
PLT  (1000/l) 209 (66–484) 209 (
Hb  (g/dL) 12.9 ± 1.7 12.7 
PTH  (pg/ml) 74.8 (24–346) 82 (2
NT-proBNP (pg/ml) 211.2 (11.7–12,633) 257.9
F (+), group with diastolic dysfunction; DF (−), group without diastolic dysfunction; eG
evels  of calcium; PLT, platelets; Hb, hemoglobin; PTH, parathormone; NT-proBNP, N-termrdiology 63 (2014) 198–204
Parameters obtained in tissue Doppler echocardiography in both
groups are demonstrated in Table 5.
Tissue Doppler echocardiography revealed in patients with LV
diastolic dysfunction, as compared to patients with normal LV dia-
stolic function, lower values of SmLV and EmLV, whereas AmLV was
similar in both groups.
ROC analysis
ROC analysis was used to evaluate both laboratory and echocar-
diographic parameters in the prediction of diastolic dysfunction.
The results are shown in Table 6.
Using ROC analysis, the value of Ca level ≤ 9.82 mg/dL was deter-
mined, characterized by a sensitivity of 91.8% in diagnosing LV
diastolic dysfunction, while having a low speciﬁcity of 38.1%.
Correlation analysis
Correlation analysis demonstrated a statistically signiﬁcant pos-
itive correlation between Ca level and EmLV, r = 0.291, p = 0.009
(Fig. 1).
A signiﬁcant correlation was obtained for NT-proBNP level and
EmLV, negative correlation, r = −0.239, p = 0.033 (Fig. 2).As for echocardiographic parameters, LVMI was  correlated
with EmLV, r = −0.358, p = 0.002. Additionally, echocardiographic
parameters such as IVSd and LVPWd correlated with EmLV,
r = −0.484, p = 0.0001 and r = −0.0469, p = 0.0001, respectively.
p (n = 39) DF (−) group (n = 42) p
 65.9 ± 11.6 0.153
13/29 0.102
10 (23) 0.481
36 (85) 0.847
10 (24) 0.203
24 (57) 0.222
6 (14) 0.074
2 (5) 0.197
29.8 ± 5.4 0.150
, chronic kidney disease; BMI, body mass index.
(n = 39) DF (−) group (n = 42) p
17 (41) 0.228
18 (43) 0.322
5 (12) 0.647
23 (55) 0.112
15 (36) 0.468
12 (29) 0.101
, angiotensin-converting enzyme; AT1, angiotensin receptor A1; Ca, calcium.
) group (n = 39) DF (−) group (n = 42) p
(0.89–6.31) 1.43 (0.68–4.2) 0.059
–79) 39 (12–89) 0.087
6–163) 54.5 (19–204) 0.059
.2–6.8) 3.6 (2.3–5.7) 0.164
± 0.76 9.44 ± 0.78 0.020
82–484) 207 (66–453) 0.089
± 1.6 13.0 ± 1.7 0.383
9.6–346) 64.3 (24–325.9) 0.144
 (32.6–12,633) 149 (11.7–966) 0.035
FR, estimated glomerular ﬁltration rate; P, serum levels of phosphorus; Ca, serum
inal pro B-type natriuretic peptide.
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Table  4
Parameters obtained in standard echocardiography in both groups.
Parameter Total (n = 81) DF (+) group (n = 39) DF (−) group (n = 42) p
LVEDD (cm) 4.6 ± 0.5 4.7 ± 0.6 4.6 ± 0.4 0.488
RVEDD (cm) 2.7 (2.1–3.3) 2.7 (2.2–3.3) 2.7 (2.1–3.3) 0.466
LAD  (cm) 4.0 ± 0.5 4.1 ± 0.5 4.0 ± 0.4 0.198
IVSd  (cm) 1.1 (0.9–1.5) 1.2 (1.0–1.5) 1.1 (0.9–1.5) 0.0008
LVPWd (cm) 1.1 (0.9–1.5) 1.2 (0.9–1.5) 1.1 (0.9–1.3) 0.0084
LVEF  (%) 59.5 ± 5.2 58.7 ± 5.5 60 ± 4.8 0.182
LVMI  (g/m2) 93.4 (57.8–210.1) 103.2 (60.1–210.1) 86.5 (57.8–165) 0.009
LVFS  (%) 31 (22–40) 30 (22–40) 31 (26–38) 0.210
E  (cm/s) 63 (35–120) 58 (35–93) 70 (45–120) 0.0004
A  (cm/s) 82 (47–146) 84 (55–146) 72.5 (46–118) 0.089
DT  (ms) 223 (101–457) 230 (133–457) 213 (101–348) 0.303
E/A  ratio 0.77 (0.42–1.9) 0.64 (0.42–1.33) 0.91 (0.59–1.9) <0.0001
DF (+), group with diastolic dysfunction; DF (−), group without diastolic dysfunction; LVEDD, left ventricular end-diastolic dimension; RVEDD, right ventricular end-diastolic
dimension; LAD, left atrial diastolic dimension; IVSd, interventricular septal diastolic diameter; LVPWd, left ventricular left ventricular posterior wall dimension at diastole;
LVEF,  left ventricular ejection fraction; LVMI, left ventricular mass index; LVFS, left ventricular fractional shortening; E, early transmitral peak velocity; A, late transmitral
peak  velocity; DT, deceleration time.
Table 5
Parameters obtained in tissue Doppler echocardiography in both groups.
Parameter Total (n = 81) DF (+) group (n = 39) DF (−) group (n = 42) p
SmLV (cm/s) 7 (4–14) 7 (5–14) 8 (4–11) 0.007
EmLV  (cm/s) 8 (3–17) 6 (3–7) 9 (8–17) <0.0001
AmLV  (cm/s) 10.0 ± 2.6 10.0 ± 2.5 10.0 ± 2.7 0.967
DF (+), group with diastolic dysfunction; DF (−), group without diastolic dysfunction; SmL
peak  late diastolic velocity.
Table 6
Receiver operating characteristics analysis of laboratory and echocardiographic
parameters in diagnosing left ventricular diastolic dysfunction.
Parameter AUC 95% CI p
NT-proBNP (pg/ml) 0.637 0.521–0.743 0.03
Ca  (mg/dL) 0.627 0.511–0.734 0.04
IVSd (cm) 0.715 0.604–0.810 0.0001
LVMI (g/m2) 0.672 0.556–0.744 0.006
SmLV (cm/s) 0.674 0.560–0.774 0.004
AUC, area under the receiver operating characteristics curve; CI, conﬁdence interval;
NT-proBNP, N-terminal proB-type natriuretic peptide; Ca, serum levels of calcium;
IVSd, interventricular septal diastolic diameter; LVMI, left ventricular mass index;
SmLV, peak mitral annular systolic velocity.
Fig. 1. Positive correlation between Ca level and peak early diastolic velocity
(EmLV).V, peak mitral annular systolic velocity; EmLV, peak early diastolic velocity; AmLV,
Univariate logistic regression
In order to determine the diagnostic value of laboratory and
echocardiographic parameters odds ratios were calculated. We
included in the analysis parameters that differed signiﬁcantly
between the groups (Table 7).
Multivariate logistic regression
Using stepwise regression, we  created a model useful for the
diagnosis of LV diastolic dysfunction in CKD patients. Only those
parameters with p < 0.1 in univariate logistic regression were con-
sidered (Table 8).Among the examined parameters, only a lowered serum Ca level
was found to be an independent predictive factor for LV diastolic
dysfunction. Other parameters did not reach statistical signiﬁcance
in multivariate analysis.
Fig. 2. Negative correlation between N-terminal proB-type natriuretic peptide (NT-
proBNP) level and peak early diastolic velocity (EmLV).
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Table  7
Evaluation of potential predictive factors for left ventricular diastolic dysfunction
(peak early diastolic velocity < 8 cm/s) in univariate logistic regression.
Parameter Odds ratio 95% CI p
Creatinine (mg/dL) 1.59 0.98–2.58 0.055
eGFR (ml/min/1.73 m2) 0.97 0.95–1.00 0.069
Urea (mg/dL) 1.01 1.00–1.02 0.031
Ca  (mg/dL) 0.49 0.25–0.93 0.026
Ca  ≤ 9.82 mg/dL 6.97 1.79–27.06 0.004
P  (mg/dL) 1.22 0.77–1.94 0.377
Log10 NT-proBNP (pg/ml) 3.13 1.12–8.77 0.026
PTH (mg/dL) 1.00 0.99–1.01 0.213
LVMI (g/m2) 1.02 1.00–1.04 0.017
IVSd (cm) 205.7 6.58–6428 0.002
LVPWd (cm) 219.98 3.94–12,279 0.01
SmLV (cm/s) 0.74 0.53–1.03 0.073
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; Ca, serum lev-
els of calcium; P, serum levels of phosphorus; NT-proBNP, N-terminal proB-type
natriuretic peptide; PTH, parathormone; LVMI, left ventricular mass index; IVSd,
interventricular septal diastolic diameter; LVPWd, left ventricular left ventricular
posterior wall dimension at diastole; SmLV, peak mitral annular systolic velocity.
Table 8
Assessment of independent predictive factors for left ventricular diastolic dysfunc-
tion (peak early diastolic velocity < 8 cm/s) in multivariate logistic regression.
Parameter Odds ratio 95% CI p
Creatinine (mg/dL) 1.43 0.41–4.96 0.563
eGFR (ml/min/1.73 m2) 1.01 0.95–1.06 0.643
Urea (mg/dL) 1.00 0.97–1.03 0.633
Ca  ≤ 9.82 mg/dL 8.81 1.49–51.82 0.014
Log10 NT-proBNP (pg/ml) 1.04 0.22–4.78 0.954
LVMI (g/m2) 1.01 0.98–1.04 0.252
IVSd (cm) 7.93 0.02–2150.5 0.460
LVPWd (cm) 0.62 0.0001–1315.3 0.903
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; Ca, serum levels
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entricular left ventricular posterior wall dimension at diastole.
iscussion
Heart failure in patients with renal dysfunctions is most com-
only caused by LV diastolic dysfunction [12–15]. Comorbidities
uch as arterial hypertension or coronary heart disease have been
ell documented as contributing factors to the development of
iastolic dysfunction. In this study, as a diagnostic criterion of LV
iastolic dysfunction we used a decreased early diastolic velocity of
he LV basal lateral wall (EmLV) < 8 cm/s, measured by pulsed wave
issue Doppler echocardiography. This value indicates the impair-
ent of LV relaxation [16]. It was especially important for us that
ll patients were optimally hydrated, and the physician performing
chocardiography did not know either the stage of renal insufﬁ-
iency or the results of laboratory tests, including electrolyte levels,
a-P metabolism, and NT-proBNP.
Patients with LV diastolic dysfunction, as compared to the
roup without diastolic dysfunction, were characterized by lower
erum Ca levels and elevated NT-proBNP levels; whereas in terms
f echocardiographic parameters, they manifested higher values
f LVMI, LVSd and LVPWd, and lower values of mitral ﬂow E
nd E/A.
Tissue Doppler echocardiography revealed that patients with
iastolic dysfunction DF (+) as compared to those without diastolic
ysfunction DF (−) were characterized by lower mitral annular
ystolic velocities (SmLV). The reduction in mitral annular sys-
olic velocity, with simultaneously preserved LV contractility in
atients with CKD, arterial hypertension, or diabetes, is most likely
ssociated with cardiac hypertrophy and ﬁbrosis. Our results con-
rm earlier reports indicating that diastolic dysfunction negatively
ffects LV systolic velocity [17–19]. Decreased systolic velocity ofrdiology 63 (2014) 198–204
mitral annulus indicates impaired cardiac contractility, and more
importantly, may  suggest an early preclinical stage of developing
cardiac failure.
In this study, we  have demonstrated that the only independent
predictive factor for LV diastolic dysfunction in the examined CKD
patients is a lowered serum Ca level. In univariate analysis, NT-
proBNP was  predictive for LV diastolic dysfunction, whereas similar
observations have been already reported [20–24]. It should be
noted that in many studies an elevated NT-proBNP level served as a
good marker of heart failure as well as an independent risk factor for
higher cardiovascular mortality in this group of patients [25–29]. In
our study, no statistically signiﬁcant correlation has been demon-
strated between the CKD stage and LV diastolic dysfunction of the
examined patients. Also, no correlation between the PTH level and
LV diastolic dysfunction has been detected, which does not con-
ﬁrm the earlier report of Hayashi et al. [30]. In their study, these
authors demonstrated that elevated PTH levels strongly correlated
with LV diastolic dysfunction in patients with advanced CKD and
eGFR < 30 ml/min [30].
To our knowledge, no previous studies have reported direct car-
diodepressive effects of lowered serum Ca levels in CKD patients.
However, there were observations of dilated cardiomyopathy
caused by hypocalcemia, that results in transient LV systolic and
diastolic dysfunction [31,32]. Limited reports concerning general
populations merely provide descriptions of single, rare cases of
acute, transient heart failure, mainly of a systolic nature, in the
course of hypocalcemia induced by primary hypoparathyroidism
[31,33–39], postoperatively [32,40,41], by immune response [42],
or toxins (alcohol) [43]. In all these described cases, systolic and
diastolic insufﬁciency was reversed following efﬁcient supple-
mentation of Ca, vitamin D3 and/or removing the toxic agent
(alcohol).
Total serum Ca comprises three forms: ionized Ca (about 45%
of total), Ca complexed with low molecular weight compounds
(approximately 15%) and protein bound Ca (on average 40%). Ca
is not only an important component of the osseous tissue, but is
also essential in coagulation processes, and is responsible for the
nerve and synaptic excitation as well as skeletal striated muscle
contraction. Ca is a mediator that transforms chemical, physical,
or hormonal stimuli into a speciﬁc biological effect. It is a compo-
nent of all cell and subcellular organelles. Pathogenesis of clinical
symptoms in hypocalcemia is mostly associated with nerve and
muscular hyperactivity. The effect of hypocalcemia on the myocar-
dial cells is unclear. We  know that the slowing down of the systolic
and diastolic function of myocardial cells and the lengthening of the
cardiomyocytes’ functional potential depend on the disturbances
in the ﬂow of ionized Ca [44]. Consequently, such disturbances
can affect the myocardial function. Unfortunately, the mechanisms
underlying disturbances in the distribution of Ca have not been
fully explained, especially due to the extremely complicated phys-
iological processes involved in Ca regulation, the more so in CKD
patients. Therefore, all the presented deliberations can only hypo-
thetically explain the effect of hypocalcemia on the LV diastolic
dysfunction in the examined CKD patients discussed in this work.
LV diastolic dysfunction can be also inﬂuenced by acid–base envi-
ronment, calciﬁcations in the cardiovascular system that change LV
diastolic parameters, intake of Ca preparations (Ca carbonicum),
which not only elevate serum Ca levels, but also induce serum
alkalization and change pH. The ultimate clinical conclusion that
can be derived from this study is that it is absolutely necessary
to control not only the levels of classical, proven, well-known
cardiac toxins, such as P and PTH, but also to skillfully control
hypocalcemia that is responsible both for a complicated chain of
biochemical reactions in the disturbed Ca-P metabolism in CKD
and for, although less clearly, affecting the diastolic function of the
heart.
l of Ca
L
c
a
t
l
C
s
D
A
w
t
l
c
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[L. Gromadzin´ski et al. / Journa
imitations of the study
Limitations of this study include, ﬁrst a relatively small, one-
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onclusions
Hypocalcemia is an independent predictive factor for LV dia-
tolic dysfunction in patients with CKD.
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